JP2012512915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512915A5 JP2012512915A5 JP2011542550A JP2011542550A JP2012512915A5 JP 2012512915 A5 JP2012512915 A5 JP 2012512915A5 JP 2011542550 A JP2011542550 A JP 2011542550A JP 2011542550 A JP2011542550 A JP 2011542550A JP 2012512915 A5 JP2012512915 A5 JP 2012512915A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- group
- acid selected
- peptide
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims description 611
- 150000001413 amino acids Chemical class 0.000 claims description 585
- 229910052700 potassium Inorganic materials 0.000 claims description 398
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 290
- 229910052740 iodine Inorganic materials 0.000 claims description 279
- 229910052720 vanadium Inorganic materials 0.000 claims description 236
- 229910052727 yttrium Inorganic materials 0.000 claims description 221
- 229910052731 fluorine Inorganic materials 0.000 claims description 208
- 229910052739 hydrogen Inorganic materials 0.000 claims description 202
- 229910052721 tungsten Inorganic materials 0.000 claims description 201
- 229910052799 carbon Inorganic materials 0.000 claims description 171
- 229910052698 phosphorus Inorganic materials 0.000 claims description 112
- 229910052717 sulfur Inorganic materials 0.000 claims description 98
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 74
- 229910052757 nitrogen Inorganic materials 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims description 55
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims description 55
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 52
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 230000003993 interaction Effects 0.000 claims description 14
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000002965 ELISA Methods 0.000 claims description 11
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 208000015294 blood coagulation disease Diseases 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 230000002860 competitive effect Effects 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 239000007850 fluorescent dye Substances 0.000 claims description 8
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 7
- 239000000975 dye Substances 0.000 claims description 7
- 108091023037 Aptamer Proteins 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000002254 cytotoxic agent Substances 0.000 claims description 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108091027076 Spiegelmer Proteins 0.000 claims description 5
- -1 and X3021 is A Inorganic materials 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- XOYSDPUJMJWCBH-VKHMYHEASA-N (3s)-3,5-diamino-5-oxopentanoic acid Chemical compound NC(=O)C[C@H](N)CC(O)=O XOYSDPUJMJWCBH-VKHMYHEASA-N 0.000 claims description 4
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- 206010053567 Coagulopathies Diseases 0.000 claims description 4
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 claims description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 4
- 230000023555 blood coagulation Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims description 2
- HOKKHZGPKSLGJE-VKHMYHEASA-N (2s)-2-(methylamino)butanedioic acid Chemical compound CN[C@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-VKHMYHEASA-N 0.000 claims description 2
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims description 2
- AXDLCFOOGCNDST-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-N 0.000 claims description 2
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 claims description 2
- BUZICZZQJDLXJN-GSVOUGTGSA-N (3R)-3-amino-4-hydroxybutanoic acid Chemical compound OC[C@H](N)CC(O)=O BUZICZZQJDLXJN-GSVOUGTGSA-N 0.000 claims description 2
- GLUJNGJDHCTUJY-RXMQYKEDSA-N (3R)-beta-leucine Chemical compound CC(C)[C@H]([NH3+])CC([O-])=O GLUJNGJDHCTUJY-RXMQYKEDSA-N 0.000 claims description 2
- PJDINCOFOROBQW-LURJTMIESA-N (3S)-3,7-diaminoheptanoic acid Chemical compound NCCCC[C@H](N)CC(O)=O PJDINCOFOROBQW-LURJTMIESA-N 0.000 claims description 2
- OFVBLKINTLPEGH-VIFPVBQESA-N (3S)-3-Amino-4-phenylbutanoic acid Chemical compound OC(=O)C[C@@H](N)CC1=CC=CC=C1 OFVBLKINTLPEGH-VIFPVBQESA-N 0.000 claims description 2
- IDNSGZOFDGAHTI-BYPYZUCNSA-N (3s)-3,6-diamino-6-oxohexanoic acid Chemical compound OC(=O)C[C@@H](N)CCC(N)=O IDNSGZOFDGAHTI-BYPYZUCNSA-N 0.000 claims description 2
- VNWXCGKMEWXYBP-YFKPBYRVSA-N (3s)-3-amino-6-(diaminomethylideneamino)hexanoic acid Chemical compound OC(=O)C[C@@H](N)CCCNC(N)=N VNWXCGKMEWXYBP-YFKPBYRVSA-N 0.000 claims description 2
- MLYMSIKVLAPCAK-LURJTMIESA-N (S)-3-Amino-5-methylhexanoic acid Chemical compound CC(C)C[C@H](N)CC(O)=O MLYMSIKVLAPCAK-LURJTMIESA-N 0.000 claims description 2
- XJODGRWDFZVTKW-UHFFFAOYSA-N -N-Methylleucine Natural products CNC(C(O)=O)CC(C)C XJODGRWDFZVTKW-UHFFFAOYSA-N 0.000 claims description 2
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 claims description 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- 108010076282 Factor IX Proteins 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 230000005526 G1 to G0 transition Effects 0.000 claims description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 2
- GDFAOVXKHJXLEI-UHFFFAOYSA-N L-N-Boc-N-methylalanine Natural products CNC(C)C(O)=O GDFAOVXKHJXLEI-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims description 2
- VUNPIAMEJXBAFP-QMMMGPOBSA-N L-beta-Homotyrosine Chemical compound OC(=O)C[C@@H](N)CC1=CC=C(O)C=C1 VUNPIAMEJXBAFP-QMMMGPOBSA-N 0.000 claims description 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 claims description 2
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 claims description 2
- DGYHPLMPMRKMPD-BYPYZUCNSA-N L-propargylglycine Chemical compound OC(=O)[C@@H](N)CC#C DGYHPLMPMRKMPD-BYPYZUCNSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 claims description 2
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 claims description 2
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 claims description 2
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 claims description 2
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 claims description 2
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 claims description 2
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 claims description 2
- XLBVNMSMFQMKEY-BYPYZUCNSA-N N-methyl-L-glutamic acid Chemical compound CN[C@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-BYPYZUCNSA-N 0.000 claims description 2
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 claims description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 108010077895 Sarcosine Proteins 0.000 claims description 2
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims description 2
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 229940000635 beta-alanine Drugs 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 229960004222 factor ix Drugs 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 229950009215 phenylbutanoic acid Drugs 0.000 claims description 2
- 229960002718 selenomethionine Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 41
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 claims 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 1
- FMUMEWVNYMUECA-UHFFFAOYSA-N L-homoleucine Natural products CC(C)CCC(N)C(O)=O FMUMEWVNYMUECA-UHFFFAOYSA-N 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13927208P | 2008-12-19 | 2008-12-19 | |
| US61/139,272 | 2008-12-19 | ||
| PCT/US2009/069060 WO2010071894A2 (en) | 2008-12-19 | 2009-12-21 | Tfpi inhibitors and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015089324A Division JP6095717B2 (ja) | 2008-12-19 | 2015-04-24 | Ｔｆｐｉインヒビターおよび使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512915A JP2012512915A (ja) | 2012-06-07 |
| JP2012512915A5 true JP2012512915A5 (enExample) | 2013-01-24 |
| JP5739816B2 JP5739816B2 (ja) | 2015-06-24 |
Family
ID=42269298
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542550A Active JP5739816B2 (ja) | 2008-12-19 | 2009-12-21 | Ｔｆｐｉインヒビターおよび使用法 |
| JP2015089324A Active JP6095717B2 (ja) | 2008-12-19 | 2015-04-24 | Ｔｆｐｉインヒビターおよび使用法 |
| JP2017024988A Active JP6567577B2 (ja) | 2008-12-19 | 2017-02-14 | Ｔｆｐｉインヒビターおよび使用法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015089324A Active JP6095717B2 (ja) | 2008-12-19 | 2015-04-24 | Ｔｆｐｉインヒビターおよび使用法 |
| JP2017024988A Active JP6567577B2 (ja) | 2008-12-19 | 2017-02-14 | Ｔｆｐｉインヒビターおよび使用法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8466108B2 (enExample) |
| EP (1) | EP2379096B1 (enExample) |
| JP (3) | JP5739816B2 (enExample) |
| KR (3) | KR101792032B1 (enExample) |
| CN (2) | CN104984319B (enExample) |
| AU (1) | AU2009327338B2 (enExample) |
| BR (2) | BR122021014783B1 (enExample) |
| CA (1) | CA2747721C (enExample) |
| DK (1) | DK2379096T3 (enExample) |
| ES (1) | ES2773766T3 (enExample) |
| HR (1) | HRP20192282T8 (enExample) |
| HU (1) | HUE046951T2 (enExample) |
| LT (1) | LT2379096T (enExample) |
| NZ (2) | NZ607892A (enExample) |
| SI (1) | SI2379096T1 (enExample) |
| WO (1) | WO2010071894A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101792032B1 (ko) | 2008-12-19 | 2017-11-02 | 백스터 인터내셔널 인코포레이티드 | Ｔｆｐｉ 억제제 및 사용 방법 |
| US8361469B2 (en) | 2008-12-22 | 2013-01-29 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| CA2777700A1 (en) * | 2009-10-14 | 2011-04-21 | Aileron Therapeutics, Inc. | Improved peptidomimetic macrocycles |
| SI3345615T1 (sl) | 2010-03-01 | 2020-03-31 | Bayer Healthcare Llc | Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI) |
| NZ603028A (en) * | 2010-03-19 | 2014-11-28 | Baxter Healthcare Sa | Tfpi inhibitors and methods of use |
| US9228022B2 (en) | 2010-06-30 | 2016-01-05 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| US9260518B2 (en) | 2010-06-30 | 2016-02-16 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| TWI483733B (zh) * | 2011-02-11 | 2015-05-11 | Baxter Int | Ｔｆｐｉ抑制劑及使用方法 |
| CA2827160A1 (en) * | 2011-02-11 | 2012-08-16 | Baxter Healthcare S.A. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| US9045526B2 (en) | 2011-06-23 | 2015-06-02 | The Regents Of The University Of Michigan | Compound and method for modulating opioid receptor activity |
| AU2013235741C1 (en) * | 2012-03-21 | 2017-12-21 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
| CN104215707B (zh) * | 2014-09-02 | 2016-01-20 | 福建中医药大学 | 栝楼桂枝汤的质量检测方法 |
| MY178445A (en) * | 2015-02-25 | 2020-10-13 | Mogam Inst Biomedical Res | Novel antibody binding to tfpi and composition comprising the same |
| CN114163531B (zh) * | 2015-08-19 | 2025-06-13 | 辉瑞公司 | 组织因子途径抑制剂抗体及其用途 |
| CN118388588A (zh) | 2019-07-08 | 2024-07-26 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| JP7152084B1 (ja) * | 2022-02-22 | 2022-10-12 | 株式会社血栓トランスレーショナルリサーチラボ | 組織因子経路インヒビターの抗凝固活性の検査試薬、検査試薬セット、および検査方法 |
Family Cites Families (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS607193B2 (ja) | 1978-01-10 | 1985-02-22 | トヨタ自動車株式会社 | 熱風循環型乾燥炉 |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5733175A (en) | 1980-07-31 | 1982-02-23 | Mitsubishi Electric Corp | Transmitter for signal of elevator |
| US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4966852A (en) * | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
| IL87171A (en) | 1987-11-23 | 1995-08-31 | Monsanto Co | cDNA of human tissue factor inhibitor |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5219994A (en) * | 1988-11-08 | 1993-06-15 | W. Alton Jones Cell Science Center, Inc. | Inhibitor of tissue factor activity |
| EP0514464A4 (en) * | 1990-02-08 | 1993-04-28 | Magainin Sciences, Inc. | Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell |
| US5466468A (en) * | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| DK146190D0 (da) | 1990-06-15 | 1990-06-15 | Novo Nordisk As | Hidtil ukendte forbindelser |
| US5622988A (en) * | 1990-06-15 | 1997-04-22 | Novo Nordisk A/S | Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time |
| US5849703A (en) * | 1990-08-27 | 1998-12-15 | G. D. Searle & Co. | Pre-formed anticoagulant heparin/TFPI complexes |
| DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
| US5197973A (en) * | 1990-12-14 | 1993-03-30 | Creative Biomolecules, Inc. | Synthetic bioadhesive |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| JPH04252954A (ja) | 1991-01-29 | 1992-09-08 | Asahi Chem Ind Co Ltd | タンパクの測定方法、試薬及びキット |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5997864A (en) * | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| JPH067193A (ja) | 1991-11-29 | 1994-01-18 | Teijin Ltd | モノクローナル抗体 |
| EP0539975A1 (en) * | 1991-10-31 | 1993-05-05 | Teijin Limited | Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor |
| IL104325A (en) | 1992-01-07 | 2000-10-31 | Novo Nordisk As | Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above |
| IL104324A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Variant of human kunitz-type protease inhibitor |
| IL104327A0 (en) * | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Variant of human kunitz-type protease inhibitor |
| IL104326A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Variant of human kunitz-type protease inhibitor |
| IL104314A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them |
| AU4784693A (en) | 1992-07-24 | 1994-02-14 | Oklahoma Medical Research Foundation | Blockade of protein c activation reduces microvascular surgical blood loss |
| JPH06153985A (ja) | 1992-11-16 | 1994-06-03 | Teijin Ltd | モノクローナル抗体 |
| NZ262679A (en) * | 1993-02-22 | 1997-08-22 | Vivorx Pharmaceuticals Inc | Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| JP3929484B2 (ja) * | 1993-09-14 | 2007-06-13 | ジェネンテック・インコーポレーテッド | エコチンおよびその同族体を含む医薬的組成物 |
| US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
| JP4137997B2 (ja) | 1994-01-11 | 2008-08-20 | ダイアックス コープ． | クニッツドメインから誘導されたヒトプラスミンの阻害剤 |
| US5902582A (en) * | 1995-09-05 | 1999-05-11 | Chiron Corporation | Use of TFPI inhibitor for treatment of cancer |
| JP3681206B2 (ja) | 1995-12-26 | 2005-08-10 | 株式会社三菱化学ヤトロン | 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用 |
| CA2279345A1 (en) * | 1997-01-31 | 1998-08-06 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
| US20050032690A1 (en) | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
| WO1999042119A1 (en) * | 1998-02-18 | 1999-08-26 | Harbor-Ucla Research And Education Institute | Antimicrobial peptides and derived metapeptides |
| JP2000128803A (ja) | 1998-10-19 | 2000-05-09 | Shionogi & Co Ltd | ティッシュ・ファクター・パスウェイ・インヒビター−２抗体 |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| KR20020042622A (ko) | 1999-07-23 | 2002-06-05 | 코애귤레이션 다이어그노스틱스, 인크. | 전혈내 응고 인자 활성을 측정하는 방법 |
| US6180607B1 (en) * | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
| US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| CA2388517A1 (en) | 1999-11-16 | 2001-05-25 | The General Hospital Corporation | Compositions and methods for regulating tumor-associated antigen expression |
| US6821775B1 (en) * | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
| US7015194B2 (en) * | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| AU5822801A (en) * | 2000-05-10 | 2001-11-20 | Novo Nordisk As | Tharmaceutical composition comprising a factor viia and a factor xiii |
| WO2001087323A2 (en) | 2000-05-16 | 2001-11-22 | Genentech, Inc. | Method for treating cartilage disorders |
| AU2002230390A1 (en) * | 2000-10-05 | 2002-04-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Ixodes scapularis tissue factor pathway inhibitor |
| CA2425829A1 (en) | 2000-10-18 | 2002-05-16 | Incyte Genomics, Inc. | Proteases |
| US7374782B2 (en) | 2000-10-27 | 2008-05-20 | Baxter International Inc. | Production of microspheres |
| US20040142892A1 (en) * | 2001-04-30 | 2004-07-22 | The University Of British Columbia | Autogene nucleic acids encoding a secretable RNA polymerase |
| US20030040480A1 (en) * | 2001-07-20 | 2003-02-27 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
| JP2004534855A (ja) | 2001-07-20 | 2004-11-18 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ因子ポリペプチドおよび第ｘｉ因子ポリペプチドを含んでなる医薬組成物 |
| EP1418890B1 (en) | 2001-08-16 | 2008-05-14 | Baxter International Inc. | Propellant-based microparticle formulations |
| US20080026068A1 (en) * | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
| US20030056474A1 (en) * | 2001-09-26 | 2003-03-27 | Chieh Szu Chung | Method of inspecting newly purchased or reground materials for making printed circuit boards |
| EP1432447A2 (en) * | 2001-09-27 | 2004-06-30 | The Board Of Regents, The University Of Texas System | Combined compositions and methods for tumor vasculature coagulation and treatment |
| EP1446145A1 (en) | 2001-11-09 | 2004-08-18 | Novo Nordisk Health Care AG | Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides |
| US7291587B2 (en) * | 2001-11-09 | 2007-11-06 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides |
| US20050214836A1 (en) * | 2002-08-30 | 2005-09-29 | Oncotherapy Science, Inc. | Method of diagnosing ovarian endometriosis |
| AU2003265866A1 (en) * | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
| EP1403638A1 (en) | 2002-09-25 | 2004-03-31 | Mondobiotech SA | Molecular methods for diagnosing interstitial lung diseases |
| WO2004063337A2 (en) | 2003-01-07 | 2004-07-29 | Dyax Corporation | Kunitz domain library |
| EP1620567A1 (en) | 2003-04-15 | 2006-02-01 | Hans-Jürgen Thiesen | Method for diagnosing rheumatoid arthritis or osteoarthritis |
| EP1650287B1 (en) | 2003-07-04 | 2012-03-28 | Beijing Grand Golden-Bright Engineering & Technologies Co. Ltd. | A method for recombining catalytic hydrocarbons |
| US20070092452A1 (en) | 2003-07-18 | 2007-04-26 | Julia Rashba-Step | Methods for fabrication, uses, compositions of inhalable spherical particles |
| US20050142205A1 (en) | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| CN1826170B (zh) | 2003-07-18 | 2010-12-08 | 巴克斯特国际公司 | 通过受控相分离制备的小球形颗粒的制造方法、其用途和成分 |
| US20050048127A1 (en) * | 2003-07-22 | 2005-03-03 | Larry Brown | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| ES2381110T3 (es) * | 2003-09-09 | 2012-05-23 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación |
| EP1664291B1 (en) | 2003-09-09 | 2012-02-29 | Novo Nordisk Health Care AG | Coagulation factor vii polypeptides |
| WO2005034844A2 (en) | 2003-09-12 | 2005-04-21 | Cleveland State University | Exosite-directed thrombin inhibitors |
| ATE557277T1 (de) | 2003-09-24 | 2012-05-15 | Oncotherapy Science Inc | Verfahren zur diagnose von endometriose mittels tfpi-2 protein |
| CN101094698A (zh) | 2003-09-29 | 2007-12-26 | 汉莫堤克科技公司 | 医学表面的生物相容,生物稳定的涂层 |
| US20090232866A1 (en) * | 2003-10-07 | 2009-09-17 | Mariann Pavone-Gyongyosi | Oligopeptides as coating material for medical products |
| US20050181978A1 (en) * | 2003-11-20 | 2005-08-18 | Rasmus Rojkjaer | Therapeutic use of factor XI |
| KR101337320B1 (ko) * | 2003-11-20 | 2013-12-06 | 사노피 파스퇴르 인크 | 백일해 독소의 정제방법 및 이에 유용한 펩타이드 |
| RU2006115783A (ru) | 2003-11-20 | 2007-12-27 | Ново Нордиск Хелс Кеа Аг (Ch) | Терапевтическое применение фактора xi |
| US20050147689A1 (en) * | 2003-12-30 | 2005-07-07 | Egilmez Nejat K. | Method for inhibiting the growth of gastrointestinal tract tumors |
| DE112005001005A5 (de) * | 2004-02-28 | 2007-05-24 | Hemoteq Gmbh | Biokompatible Beschichtung, Verfahren und Verwendung von medizinischen Oberflächen |
| EP1750758A1 (en) | 2004-05-11 | 2007-02-14 | Novo Nordisk Health Care AG | Use of factor viia for the treatment of burn traumas |
| CA2566075A1 (en) | 2004-05-12 | 2005-12-01 | Baxter Healthcare S.A. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
| US8728525B2 (en) * | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
| WO2005115442A1 (en) | 2004-05-25 | 2005-12-08 | Novo Nordisk Health Care Ag | Use of coagulation factor xiii for treatment of post surgical bleedings |
| US7767654B2 (en) | 2004-05-27 | 2010-08-03 | Baxter International, Inc. | Methods for treating bleeding disorders using sulfated polysaccharides |
| WO2005123916A2 (en) | 2004-06-21 | 2005-12-29 | Novo Nordisk Health Care Ag | Glycosylation-disrupted factor vii variants |
| US20090004175A1 (en) | 2004-07-16 | 2009-01-01 | Novo Nordick Health Care A/G | Methods for Optimizing Forming Vlla-Based Hemostatic Treatment |
| US20060040896A1 (en) | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| BRPI0406057B1 (pt) | 2004-09-15 | 2021-10-26 | União Química Farmacêutica Nacional S/A | Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante |
| JP4252954B2 (ja) | 2004-12-02 | 2009-04-08 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム |
| EP1855712A2 (en) | 2005-02-28 | 2007-11-21 | Novo Nordisk Health Care AG | Fxiii variants with improved properties |
| ATE505488T1 (de) | 2005-03-04 | 2011-04-15 | Univ Illinois | Modulator von coagulationskaskaden und fibrinolytischen kaskaden |
| JP2008539259A (ja) | 2005-04-27 | 2008-11-13 | バクスター・インターナショナル・インコーポレイテッド | 表面を修飾した微粒子およびその形成方法および使用 |
| KR20080008364A (ko) * | 2005-05-05 | 2008-01-23 | 헤모텍 아게 | 관 스텐트의 전면 코팅 |
| WO2006128497A1 (en) | 2005-06-01 | 2006-12-07 | Novo Nordisk A/S | Pharmaceutical formulation of factor xi |
| WO2007014749A2 (en) | 2005-07-29 | 2007-02-08 | Universiteit Van Maastricht | Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor |
| DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| GB0525999D0 (en) | 2005-12-21 | 2006-02-01 | Ares Trading Sa | Novel members of the kazal family of serine protease inhibitors |
| US8287940B2 (en) * | 2006-02-09 | 2012-10-16 | B. Braun Melsungen Ag | Coating method for a folded balloon |
| US20070192033A1 (en) * | 2006-02-16 | 2007-08-16 | Microsoft Corporation | Molecular interaction predictors |
| US9096839B2 (en) * | 2006-04-26 | 2015-08-04 | Arteriocyte Medical Systems, Inc. | Compositions and methods of preparation thereof |
| US20070281031A1 (en) * | 2006-06-01 | 2007-12-06 | Guohan Yang | Microparticles and methods for production thereof |
| EP1892303A1 (en) | 2006-08-22 | 2008-02-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung |
| EP1895436A1 (en) * | 2006-08-31 | 2008-03-05 | Silicos NV | Method for evolving molecules and computer program for implementing the same |
| EP1913962A1 (en) | 2006-10-22 | 2008-04-23 | Ophir Perelson | Expandable medical device for the treatment and prevention of cardiovascular diseases |
| JP5679663B2 (ja) | 2007-02-23 | 2015-03-04 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 海藻抽出物からのフコイダン精製のためのプロセスの方法 |
| EP1972687A1 (en) | 2007-03-23 | 2008-09-24 | GenOdyssee | Polynucleotides and polypeptides of human factor VII gene, SNPs |
| WO2008127654A2 (en) | 2007-04-11 | 2008-10-23 | The University Of North Carolina At Chapel Hill | Methods and compositions for intra-articular coagulation proteins |
| US20090054332A1 (en) * | 2007-06-21 | 2009-02-26 | Conjuchem Biotechnologies, Inc. | Thombopoietin peptide conjugates |
| ES2597436T3 (es) | 2007-09-28 | 2017-01-18 | Portola Pharmaceuticals, Inc. | Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos |
| US20100297257A1 (en) | 2007-11-09 | 2010-11-25 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) | Anticoagulant antagonist and hemophillia procoagulant |
| CN101952309A (zh) | 2007-12-21 | 2011-01-19 | Ifxa有限公司 | 蛋白酶抑制剂 |
| FR2934052B1 (fr) | 2008-07-17 | 2011-11-25 | Stago Diagnostica | Dosage de l'activite du facteur tissulaire circulant |
| UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| KR100994996B1 (ko) | 2008-08-06 | 2010-11-18 | 한국과학기술연구원 | 페난트렌 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법 |
| AU2009279090A1 (en) | 2008-08-06 | 2010-02-11 | Novo Nordisk Health Care Ag | Conjugated proteins with prolonged in vivo efficacy |
| KR101792032B1 (ko) | 2008-12-19 | 2017-11-02 | 백스터 인터내셔널 인코포레이티드 | Ｔｆｐｉ 억제제 및 사용 방법 |
| NZ603028A (en) | 2010-03-19 | 2014-11-28 | Baxter Healthcare Sa | Tfpi inhibitors and methods of use |
| SG193594A1 (en) | 2011-04-01 | 2013-10-30 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| EP2808081A4 (en) | 2012-01-23 | 2015-08-26 | N E Chemcat Corp | BARIUM SULPHATE CONTAINING ALUMINUM MATERIAL AND EXHAUST GAS CLEANING CATALYST THEREOF |
| JP6153985B2 (ja) | 2015-10-16 | 2017-06-28 | 株式会社スクウェア・エニックス | ビデオゲーム処理プログラム、ビデオゲーム処理システム及びビデオゲーム処理方法 |
-
2009
- 2009-12-21 KR KR1020117016656A patent/KR101792032B1/ko active Active
- 2009-12-21 CN CN201510260670.1A patent/CN104984319B/zh active Active
- 2009-12-21 ES ES09833887T patent/ES2773766T3/es active Active
- 2009-12-21 DK DK09833887T patent/DK2379096T3/da active
- 2009-12-21 SI SI200932012T patent/SI2379096T1/sl unknown
- 2009-12-21 HR HRP20192282TT patent/HRP20192282T8/hr unknown
- 2009-12-21 JP JP2011542550A patent/JP5739816B2/ja active Active
- 2009-12-21 NZ NZ607892A patent/NZ607892A/en unknown
- 2009-12-21 US US12/643,818 patent/US8466108B2/en active Active
- 2009-12-21 NZ NZ593815A patent/NZ593815A/xx unknown
- 2009-12-21 BR BR122021014783-3A patent/BR122021014783B1/pt active IP Right Grant
- 2009-12-21 LT LTEP09833887.4T patent/LT2379096T/lt unknown
- 2009-12-21 KR KR1020187036883A patent/KR102165021B1/ko active Active
- 2009-12-21 WO PCT/US2009/069060 patent/WO2010071894A2/en not_active Ceased
- 2009-12-21 HU HUE09833887A patent/HUE046951T2/hu unknown
- 2009-12-21 EP EP09833887.4A patent/EP2379096B1/en active Active
- 2009-12-21 BR BRPI0922344A patent/BRPI0922344A2/pt not_active Application Discontinuation
- 2009-12-21 CA CA2747721A patent/CA2747721C/en active Active
- 2009-12-21 CN CN200980156547.8A patent/CN102348462B/zh active Active
- 2009-12-21 AU AU2009327338A patent/AU2009327338B2/en active Active
- 2009-12-21 KR KR1020177030751A patent/KR101977846B1/ko active Active
-
2013
- 2013-03-14 US US13/827,160 patent/US9777051B2/en active Active
-
2015
- 2015-04-24 JP JP2015089324A patent/JP6095717B2/ja active Active
-
2017
- 2017-02-14 JP JP2017024988A patent/JP6567577B2/ja active Active
- 2017-08-18 US US15/681,074 patent/US11001613B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512915A5 (enExample) | ||
| CN104984319B (zh) | Tfpi抑制剂和使用方法 | |
| US6217846B1 (en) | Synthetic peptides for use in thrombus detection | |
| JP2013522291A5 (enExample) | ||
| PT2360258E (pt) | Moléculas para transportar um composto através da barreira hematoencefálica | |
| US7074765B2 (en) | Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 | |
| WO2005119266A1 (en) | Sr-a antagonists | |
| JP2680552B2 (ja) | 修飾低密度リポ蛋白質に対する結合活性を有するペプチド誘導体 | |
| AU2017203999B2 (en) | Tfpi inhibitors and methods of use | |
| US20230095144A1 (en) | Amyloid inhibitory peptides | |
| Tousignant et al. | Characterization of NK-1 receptors in guinea pig and rat brain membranes with NK-1 peptides and a non-peptide antagonist | |
| JPWO2023171577A5 (enExample) | ||
| HK1163516B (en) | Tfpi inhibitors and methods of use | |
| HK1163516A (en) | Tfpi inhibitors and methods of use |